APOE Switching Meets FDA Reality: Why Alzheimer’s Translation Now Runs on Biomarkers and Trial Architecture
Elegant Alzheimer’s biology is no longer enough. In 2026, biomarker strategy, patient selection, and auditable trial design decide which programs survive translation.